Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Candida auris, a multidrug-resistant yeast that causes invasive infections, was first described in 2009 in Japan and has since been reported from several countries. METHODS: To understand the global emergence and epidemiology of C. auris, we obtained isolates from 54 patients with C. auris infection from Pakistan, India, South Africa, and Venezuela during 2012-2015 and the type specimen from Japan. Patient information was available for 41 of the isolates. We conducted antifungal susceptibility testing and whole-genome sequencing (WGS). RESULTS: Available clinical information revealed that 41% of patients had diabetes mellitus, 51% had undergone recent surgery, 73% had a central venous catheter, and 41% were receiving systemic antifungal therapy when C. auris was isolated. The median time from admission to infection was 19 days (interquartile range, 9-36 days), 61% of patients had bloodstream infection, and 59% died. Using stringent break points, 93% of isolates were resistant to fluconazole, 35% to amphotericin B, and 7% to echinocandins; 41% were resistant to 2 antifungal classes and 4% were resistant to 3 classes. WGS demonstrated that isolates were grouped into unique clades by geographic region. Clades were separated by thousands of single-nucleotide polymorphisms, but within each clade isolates were clonal. Different mutations in ERG11 were associated with azole resistance in each geographic clade. CONCLUSIONS: C. auris is an emerging healthcare-associated pathogen associated with high mortality. Treatment options are limited, due to antifungal resistance. WGS analysis suggests nearly simultaneous, and recent, independent emergence of different clonal populations on 3 continents. Risk factors and transmission mechanisms need to be elucidated to guide control measures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“C. auris, a novel Candida species first identified in 2009, has emerged since 2013 as a cause of nosocomial outbreaks in multiple countries across 5 continents.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [16]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resistance to all three classes of antifungals is reported most commonly in India in South Asia (3%), whereas this is much less common in other regions of the world.122–124”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [122]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Invasive C. auris infections are associated with high mortality rates, with 60% of hospitalizations due to C. auris infections resulting in death (8).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three such mutations, encoding the amino acid substitutions VF125AL (commonly referred to as F126L), Y132F, and K143R, are frequently reported among fluconazole-resistant clinical isolates, and associations between these mutations and specific genetic clades of C. auris have been observed (2).”
From Mutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, up to 96% of C. auris may exhibit resistance to fluconazole, an exceptionally high value compared to 0.5–2% for C. albicans, 4–9% for C. tropicalis, 2–6% for C. parapsilosis, and 11–13% for C. glabrata [16,40,41].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [16]
Experimental — accuracy not yet measured
29 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0
Tamura, K., Stecher, G., Peterson, D., Filipski, A., & Kumar, S. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst197 · Cited by 47,205
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895 · cited 1×
“SNPs were identified using 2 independent pipelines, as described elsewhere (see also the legend to Supplemental Figure 1) [15, 19].”
MethodEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“auris because we did not have a comparison group of patients with other Candida infections from the same institutions [31].”
BackgroundResultNonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data
Chin, C.-S., Alexander, D. H., Marks, P., Klammer, A. A., Drake, J., Heiner, C., Clum, A., Copeland, A., Huddleston, J., Eichler, E. E., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2474 · Cited by 4,029 · cited 1×
“The reference genome was generated by de novo assembly of PacBio reads from isolate B8441, as described elsewhere [18], and used as a reference for single-nucleotide polymorphism (SNP) calling.”
MethodSatoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381 · cited 8×
“To understand the global emergence and epidemiology of C. auris, we obtained isolates from 54 patients with C. auris infection from Pakistan, India, South Africa, and Venezuela during 2012–2015 and the type specimen from Japan.”
BackgroundInfluentialEvolution of pathogenicity and sexual reproduction in eight Candida genomes
Butler, G., Rasmussen, M. D., Lin, M. F., Santos, M. A. S., Sakthikumar, S., Munro, C. A., Rheinbay, E., Grabherr, M., Forche, A., Reedy, J. L., et al. (2009) · Nature · doi:10.1038/nature08064 · Cited by 1,065 · cited 1×
“5 Mb, similar to that of other Candida species [25].”
BackgroundSelf-citationKathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532 · cited 1×
“It phenotypically resembles Candida haemulonii and requires use of molecular methods for identification [9, 10].”
MethodSelf-citationFirst Three Reported Cases of Nosocomial Fungemia Caused by Candida auris
Lee, W. G., Shin, J. H., Uh, Y., Kang, M. G., Kim, S. H., Park, K. H., & Jang, H.-C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00319-11 · Cited by 523 · cited 2×
“auris [3], establishing that this new species was capable of causing invasive infections.”
BackgroundPerea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470
Incidence, characteristics and outcome of ICU-acquired candidemia in India
Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., Kaur, H., Capoor, M., Chhina, D., Rao, R., Eshwara, V. K., Xess, I., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-014-3603-2 · Cited by 454 · cited 1×
“auris may become widely established within certain regions, as evidenced by the fact that it now accounts for nearly 5% of candidemia in Indian intensive care units [5].”
Background
Cited by
Items 801–900 of 1,007
The Gordian Knot of C. auris: If You Cannot Cut It, Prevent It
Rapti, V., Iliopoulou, K., & Poulakou, G. (2023) · Pathogens · doi:10.3390/pathogens12121444 · Cited by 20
Komorowski, A. S., Aftanas, P., Porter, V. R., Katz, K. C., Kozak, R. A., & Li, X. X. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae017 · Cited by 17
Whole Genome Sequencing Applications in Hospital Epidemiology and Infection Prevention
Doll, M. E., Bryson, A. L., & Palmore, T. N. (2024) · Current Infectious Disease Reports · doi:10.1007/s11908-024-00836-w · Cited by 16
Retore, Y. I., Lucini, F., Rial, R. C., Cardoso, C. A. L., Souza, P. F. N., Simionatto, S., & Rossato, L. L. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118240 · Cited by 18
Comparative fitness trade-offs associated with azole resistance in Candida auris clinical isolates
Das, S. K., Singh, S., Tawde, Y., Dutta, T. K., Rudramurthy, S. M., Kaur, H., Shaw, T., & Ghosh, A. K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32386 · Cited by 17
“After its first report in 2009 from a 70 year old female with otitis from Japan [2], this pathogen has been reported from 42 countries across six continents till date [3,4].”
BackgroundAntifungal resistance: why are we losing this battle?
Macedo, J. D. P., & Dias, V. C. (2024) · Future Microbiology · doi:10.1080/17460913.2024.2342150 · Cited by 19
Diseases Transmitted to Humans through Foodborne Microbes in the Global South
Oduoye, M. O., Akilimali, A., Karim, K. A., Moradeyo, A. A., Zubairu, A. Z., Muzata, D., Christopher, G. U., Chipinga, J., Simiyu, B. W., & Isiko, I. (2024) · Springer eBooks · doi:10.1007/978-981-97-2428-4_18 · Cited by 22
Candida auris: A focused review for emergency clinicians
Long, B., Lacy, A. J., Koyfman, A., & Liang, S. Y. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.07.062 · Cited by 18
Characterization of susceptibility patterns and adaptability of the newly emerged Candida auris
Semenya, M. D., Aladejana, A. E., & Ndlovu, S. I. (2024) · International Microbiology · doi:10.1007/s10123-024-00563-1 · Cited by 16
Jiménez, A., Rosa, R. M., Ayoub, S., Guran, R., Arenas, S. P., Valencia, N., Stabile, J. C., Estepa, A. T., Parekh, D. J., Ferreira, T., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae411 · Cited by 16
Exploration of novel mechanisms of azole resistance in Candida auris
Li, J., Brandalise, D., Coste, A. T., Sanglard, D., & Lamoth, F. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01265-24 · Cited by 19
“The K143R variant has been reported among clinical C. auris isolates, and its role in azole resistance has been demonstrated (5, 15, 16, 20).”
Rapid spread of Candida auris in China after COVID-19
Bing, J., Huang, Y., Du, H., Guo, P., Cao, J., Kang, M., Nobile, C. J., & Huang, G. (2025) · Journal of Infection · doi:10.1016/j.jinf.2025.106476 · Cited by 17
“6 Moreover, we identified several other mutations in the genes TAC1B, CDR1, and MDR1 that could also contribute to antifungal resistance in clinical strains of C. auris.”
Belay, W. Y., Getachew, M., Tegegne, B. A., Teffera, Z. H., Dagne, A., Zeleke, T. K., Wondm, S. A., Abebe, R. B., Gedif, A. A., Fenta, A., et al. (2025) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361251340144 · Cited by 34
“69 Currently, the majority of antifungal drugs become ineffective due to antifungal resistance.”
Screening the CALIBR ReFRAME Library in Search for Inhibitors of Candida auris Biofilm Formation
Wall, G., Chen, E., Hull, M. V., & Lopez-Ribot, J. L. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.597931 · Cited by 20
“Since its first identification as a causative agent of infection in humans in 2009, Candida auris has emerged as a formidable opportunistic pathogenic yeast and rapidly spread throughout the world (Chowdhary et al., 2016; Chowdhary et al., 2017; Lockhart et al., 2017; Kean et al., 2020).”
BackgroundCatalytic defense against fungal pathogens using nanozymes
Wu, Q., Zou, S., Wang, Q., Chen, L., Yan, X., & Gao, L. (2021) · Nanotechnology Reviews · doi:10.1515/ntrev-2021-0084 · Cited by 16
Ceragenin-Coated Non-Spherical Gold Nanoparticles as Novel Candidacidal Agents
Skłodowski, K., Chmielewska, S. J., Depciuch, J., Deptuła, P., Piktel, E., Daniluk, T., Zakrzewska, M., Czarnowski, M., Cieśluk, M., Durnaś, B., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111940 · Cited by 16
“There is a growing number of drug-resistant fungi, including multi-drug resistant (MDR) strains on four continents, namely: Asia (Pakistan, India, and Japan), Africa (South Africa), South America (Venezuela) [16], and North America (USA/Canada) [17].”
BackgroundLim, H. J., Choi, M. J., Byun, S. A., Won, E. J., Park, J.-H., Choi, Y. J., Choi, H., Choi, H.-W., Kee, S., Kim, S. H., et al. (2023) · Journal of Fungi · doi:10.3390/jof9050515 · Cited by 19
“auris is an emerging MDR yeast that has caused healthcare-associated outbreaks in numerous countries [5].”
BackgroundCandidemia in the patient with malignancy
Alves, J., Palma, P., Azevedo, D., & Rello, J. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1508290 · Cited by 19
“Candida auris, a trending emerging pathogen [18,19] with”
BackgroundAntifungal Resistance Testing and Implications for Management
Badali, H., & Wiederhold, N. P. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00354-6 · Cited by 17
Fungal cell death: The beginning of the end
Rico-Ramírez, A. M., Gonçalves, A. P., & Glass, N. L. (2022) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2022.103671 · Cited by 19
Lanna, M., Lovatto, J. E., de Almeida, J. N., Medeiros, E. A., Colombo, A. L., & García‐Effrón, G. (2025) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2025.101546 · Cited by 16
Self-citationCandida auris : host interactions, antifungal drug resistance, and diagnostics
Chowdhary, A., Lionakis, M. S., & Chauhan, N. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00187-22 · Cited by 22
“C. auris is a multidrug-resistant fungal pathogen that was first identified in 2009 from an ear infection of a patient in Japan (28, 29).”
Self-citationIn Vivo Efficacy of Amphotericin B against Four Candida auris Clades
Forgács, L., Borman, A. M., Kovács, R., Balázsi, D., Tóth, Z., Balázs, B., Chun-Ju, C., Kardos, G., Kovacs, I., & Majoros, L. (2022) · Journal of Fungi · doi:10.3390/jof8050499 · Cited by 18
Candida auris Identification and Profiling by MALDI–ToF Mass Spectrometry
Abdolrasouli, A., & Fraser, M. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2417-3_2 · Cited by 15
Politi, L., Vrioni, G., Hatzianastasiou, S., Lada, M., Martsoukou, M., Sipsas, N. V., Chini, M., Baka, V., Kafkoula, E., Masgala, A., et al. (2024) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2024.101477 · Cited by 17
Balázsi, D., Tóth, Z., Locke, J. B., Borman, A. M., Forgács, L., Balla, N., Kovács, F., Kovács, R., Amano, C., Baran, T. I., et al. (2024) · Journal of Fungi · doi:10.3390/jof10090617 · Cited by 17
“Most clinical isolates were resistant to fluconazole and, to a lesser extent, amphotericin B [2,3].”
BackgroundAcquired amphotericin B resistance attributed to a mutated ERG3 in Candidozyma auris
Massic, L., Doorley, L. A., Jones, S. J., Richardson, I., Siao, D. D., Siao, L., Dykema, P., Hua, C. N., Schneider, E., Cuomo, C. A., et al. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00601-25 · Cited by 15
Self-citationZhang, H., Niu, Y., Tan, J., Liu, W., Sun, M.-A., Yang, E., Wang, Q., Li, R., Wang, Y., & Liu, W. Y. (2019) · mSystems · doi:10.1128/msystems.00459-19 · Cited by 15
de Ullivarri, M. F., Bulacios, G. A., Navarro, S. A., Lanza, L., Mendoza, L. M., & Chalón, M. C. (2020) · Medical Mycology · doi:10.1093/mmy/myaa011 · Cited by 24
Vij, R., Hube, B., & Brunke, S. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.02.003 · Cited by 16
“Some opportunistic fungi like Candida auris and Lomentospora prolificans are naturally resistant to many antimycotics [5,6].”
BackgroundMolecular Mechanisms of Resistance to Antifungals in Candida albicans
Ruiz‐Baca, E., Arredondo-Sánchez, R. I., Corral-Pérez, K., López-Rodríguez, A., Meneses‐Morales, I., Ayala‐García, V. M., & Martínez-Rocha, A. L. (2021) · Infectious diseases · doi:10.5772/intechopen.96346 · Cited by 23
de Jong, A. W., Francisco, E. C., de Almeida, J. N., Brandão, I. B., Pereira, F. M., Dias, P. H. P., Costa, M. M. D. M., Jordão, R. T. D. S., Vu, D., Colombo, A. L., et al. (2021) · Mycopathologia · doi:10.1007/s11046-021-00593-7 · Cited by 15
“auris genome data was generated by short-read Illumina sequencing [3, 9, 11, 12].”
MethodSelf-citationComparing genomic variant identification protocols for Candida auris
Xiao, L., Muñoz, J. F., Gade, L., Argimón, S., Bougnoux, M., Bowers, J. R., Chow, N. A., Cuesta, I., Farrer, R. A., Maufrais, C., et al. (2023) · Microbial Genomics · doi:10.1099/mgen.0.000979 · Cited by 15
“Each group used a dataset of 35 isolates representing each of the 4 major C. auris clades [5], including closely related isolates from the same outbreak.”
InfluentialSelf-citationKumar, Y., Wani, F. A., Ahmedi, S., Shamsi, A., Nadeem, M., Manzoor, N., Kamli, M. R., Malik, M. A., Rizvi, M. M. A., & Patel, R. (2024) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2024.124631 · Cited by 16
Roscini, L., Vassiliou, A. G., Corte, L., Pierantoni, D. C., Robert, V., Tascini, C., Mattana, S., Cardinali, M. A., Orfanos, S. E., Fioretto, D., et al. (2018) · Infectious Diseases and Therapy · doi:10.1007/s40121-018-0191-4 · Cited by 16
“These results (the larger the thickness, the more plastic the behavior, and the more intense the Raman signals) can be consistently interpreted in terms of a region in which a chemico-physical condition is preserved that is favorable to the survival of Candida cells.”
BackgroundInfluentialFirst Report of Candida auris Spondylodiscitis in Oman: A Rare Presentation
Supreeth, S., Ghafri, K. A. A., Jayachandra, R. K., & Balushi, Z. Y. A. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.09.021 · Cited by 16
Buil, J. B., van der Lee, H. A. L., Curfs-Breuker, I., Verweij, P. E., & Meis, J. F. G. M. (2019) · Journal of Fungi · doi:10.3390/jof5040094 · Cited by 17
Self-citationInnovative therapies for invasive fungal infections in preclinical and clinical development
Yu, Y., Albrecht, K., Gröll, J., & Beilhack, A. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1791819 · Cited by 19
Widespread Foodborne Cyclosporiasis Outbreaks Present Major Challenges
Colley, D. G. (1996) · Emerging infectious diseases · doi:10.3201/eid0204.960413 · Cited by 16
Aşkun, T. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100869 · Cited by 16
Mochochoko, B. M., Pohl, C. H., & O’Neill, H. G. (2022) · iScience · doi:10.1016/j.isci.2022.105870 · Cited by 14
The utility of Drosophila melanogaster as a fungal infection model
Mpamhanga, C. D., & Kounatidis, I. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1349027 · Cited by 15
Prayag, P. S., Patwardhan, S. A., Joshi, R., Dhupad, S., Rane, T., & Prayag, A. (2024) · Medical Mycology · doi:10.1093/mmy/myae065 · Cited by 15
Mitchell, B. I., Kling, K., Bolon, M. K., Rathod, S. N., Malczynski, M., Ruiz, J., Polanco, W., Fritz, K., Maali, S., Stosor, V., et al. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.00680-24 · Cited by 15
“SNPs were identified by aligning short reads to the complete C. auris reference genome CA01 as previously described (18).”
InfluentialEarly Introductions of Candida auris Detected by Wastewater Surveillance, Utah, USA, 2022–2023
Chavez, J., Crank, K. C., Barber, C. A., Gerrity, D. W., Iverson, T., Mongillo, J., Weil, A., Rider, L. J., LaCross, N. C., Oakeson, K. F., et al. (2024) · Emerging infectious diseases · doi:10.3201/eid3010.240173 · Cited by 15
Antimicrobial properties and biocompatibility of semi-synthetic carbohydrate-based ionic hydrogels
Lambrecht, S., Gazizova, A., Kara, S., Meyer, J., & Jopp, S. (2024) · RSC Advances · doi:10.1039/d4ra05695g · Cited by 14
“51 In vitro biocompatibility Eluate tests.”
Gul, F., Ullah, Z., Iqbal, J., Abbasi, B. A., Ali, S., Kanwal, S., Uddin, J., Kazi, M., & Mahmood, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-87670-9 · Cited by 14
de Melo, C. C., de Oliveira, H. L. N. L., Souza, B. R., Moura, C. V. R., Oliveira, R., Bastos, R. W., Kemmerich, K. K., de Almeida, J. N., Colombo, A. L., Spruijtenburg, B., et al. (2025) · Mycoses · doi:10.1111/myc.70085 · Cited by 14
“This emerging pathogen is known for the high genetic diversity and can be separated into distinct phylogenetic clades, displaying peculiarities of geographic distribution, virulence, and resistance [3–5].”
Self-citationGenetic Evaluation of Nosocomial Candida auris Transmission
Roberts, S. C., Zembower, T. R., Ozer, E. A., & Qi, C. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.02252-20 · Cited by 15
“isolates by tens of thousands of SNVs (12).”
BackgroundAssessment of the In Vitro and In Vivo Antifungal Activity of NSC319726 against Candida auris
Li, J., Coste, A. T., Bachmann, D., Sanglard, D., & Lamoth, F. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01395-21 · Cited by 14
“and can affect all three current antifungal classes (azoles, polyenes, and echinocandins) (2).”
BackgroundTiburcio, M. A., Rocha, A. R., Romano, R. A., Inada, N. M., Bagnato, V. S., Carlos, R. M., & Buzzá, H. H. (2022) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2022.112414 · Cited by 15
Clonal Dissemination of Antifungal-Resistant Candida haemulonii , China
Chen, X., Jia, X., Bing, J., Zhang, H., Hong, N., Liu, Y., Xi, H., Wang, W., Liu, Z., Zhang, Q., et al. (2023) · Emerging infectious diseases · doi:10.3201/eid2903.221082 · Cited by 16
Torres, R., Barreto-Santamaría, A., Arévalo‐Pinzón, G., Firacative, C., Gómez, B. L., Escandón, P., Patarroyo, M. A., & Muñoz, J. E. (2023) · Antibiotics · doi:10.3390/antibiotics12081234 · Cited by 20
“auris has emerged as an important nosocomial pathogen, causing between 5% and 30% of all candidemia cases worldwide, affecting patients mainly in intensive care units (ICUs), and being associated with high crude mortalities ranging between 33% and 100%, which are the result of therapeutic failure due to antifungal res…”
BackgroundCandida auris in skilled nursing facilities
Yune, P. S., Coe, J., Rao, M., & Lin, M. Y. (2023) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361231189958 · Cited by 23
Peng, Y., Liu, Y., Yu, X., Fang, J., Guo, Z., Liao, K., Chen, P., & Guo, P. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2300525 · Cited by 15
“These clades were found to di ff er from each other by thousands of single-nucleotide polymorphisms through whole genome sequencing (WGS) analyses [9, 10].”
BackgroundAwad, L. S., Tamim, H., Abdallah, D., Salameh, M. A., Mugharbil, A., Jisr, T., Zahran, K., Droubi, N., Ibrahim, A., & Moghnieh, R. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3512-z · Cited by 15
Primer aislamiento de Candida auris en Chile
Moreno, M. V., Simian, M. E., Villarroel, J., Fuenzalida, L. M., Yarad, M. F., Soto, A., Silva, V., & Pimentel, X. (2019) · Revista chilena de infectología · doi:10.4067/s0716-10182019000600767 · Cited by 19
A Novel Transdermal Application for Clearing Skin Colonization by Candida auris
Ghannoum, M. A., Herrada, J., McCormick, T. S., & Long, L. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02303-20 · Cited by 15
“were receiving systemic antifungal treatment (7).”
Detecting DNA of novel fungal pathogens using ResNets and a curated fungi-hosts data collection
Bartoszewicz, J. M., Nasri, F., Nowicka, M., & Renard, B. Y. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac495 · Cited by 16
Chamberland, M. E., Epstein, J. S., Dodd, R. Y., Persing, D. H., Will, R. G., DeMaria, A., Emmanuel, J., Pierce, B., & KHABBAZ, R. F. (1998) · Emerging infectious diseases · doi:10.3201/eid0403.980317 · Cited by 15
Tracking a Global Threat: a New Genotyping Method for Candida auris
Cuomo, C. A., & Alanio, A. (2020) · mBio · doi:10.1128/mbio.00259-20 · Cited by 14
“Amino acid substitutions associated with azole and echinocandin resistance have been identified in most resistant isolates (4, 7, 8).”
BackgroundSelf-citationKatsiari, M., Nikolaou, C., Palla, E., Theodoridou, K., Tsakris, A., & Vrioni, G. (2025) · Pathogens · doi:10.3390/pathogens14040328 · Cited by 13
Brouwer, C. P. J. M., van der Linden, Y., Carrasco, M. R., Alwasel, S. H., Abalkhail, T., Al-Otibi, F. O., Boekhout, T., & Welling, M. M. (2025) · Antibiotics · doi:10.3390/antibiotics14070671 · Cited by 13
“For instance, Cz. auris strains belonging to the South Asia and South Africa clades have different ERG11 mutations, while no mutation was reported for the strain from Japan (East Asia clade) [20].”
Gherbawy, Y. A. M. H., Al-Harthi, H. F., El-Dawy, E., Gaber, M., Peț, I., Wang, L., Hu, P., & Hussein, M. (2025) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2025.2569931 · Cited by 13
“Next-generation sequencing (NGS) and whole-genome sequencing (WGS) now enable differentiation at the strain level, facilitate outbreak investigations, and support resistance profiling (Lockhart et al. 2017).”
InfluentialBing, J., Li, S., Ji, L., Du, H., Shamoon, N. M., Nobile, C. J., & Huang, G. (2026) · Clinical Microbiology Reviews · doi:10.1128/cmr.00394-25 · Cited by 15
Amann, V., Kissmann, A., Mildenberger, V., Krebs, I., Perez‐Erviti, J. A., Martell-Huguet, E. M., Otero‐González, A. J., Morales-Vicente, F., Rodríguez-Castaño, G. P., Firacative, C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129788 · Cited by 13
“auris, treatment of Candida infections is quite demanding, as resistance to all classes of available antifungals is already widespread and still increasing, especially with multidrug resistance being a true challenge [19,20].”
BackgroundInfluentialBroad susceptibility of Candida auris strains to 8-hydroxyquinolines and mechanisms of resistance
Lohse, M. B., Laurie, M. T., Levan, S., Ziv, N., Ennis, C. L., Nobile, C. J., DeRisi, J. L., & Johnson, A. D. (2023) · mBio · doi:10.1128/mbio.01376-23 · Cited by 16
“It was first reported in Japan in 2009 (12) and was subsequently found to have five clades (I–V) that localize to distinct geographic locations (13, 14).”
Schutz, K., Melie, T., Smith, S. D., & Quandt, C. A. (2024) · Microbial Genomics · doi:10.1099/mgen.0.001233 · Cited by 13
Honorato, L., Bonilla, J. J. A., da Silva, L. R., Kornetz, J., Zamith‐Miranda, D., Valdez, A. F., Nosanchuk, J. D., Fox, E. G. P., & Nimrichter, L. (2024) · Virulence · doi:10.1080/21505594.2024.2413329 · Cited by 13
Alvarado, M., Navajas, J. A. G., Muñoz, M. T. B., Gómez-Molero, E., Fernández-Sánchez, S., Eraso, E., Munro, C. A., Valentín, E., Mateo, E., & de Groot, P. W. J. (2024) · FEMS Yeast Research · doi:10.1093/femsyr/foae039 · Cited by 14
“…environments and care homes, easy transmission, and high drug resistance, in most cases to fluconazole but in some cases to polyenes and/or echinocandins (Arendrup et al. 2017 , Chowdhary et al. 2017 , Lockhart et al. 2017 , Centers for Disease Control and Prevention 2024 , Lockhart et al. 2023 ).”
Key Factors to Consider for Candida auris Screening in Healthcare Settings: A Systematic Review
Danielsen, A. S., Ødeskaug, L. E., Raastad, R., Kjerulf, A., Andersen, A., Tornes, R. A., Himmels, J. P. W., Dahle, U. R., Sare, M., Kristensen, B., et al. (2025) · Mycoses · doi:10.1111/myc.70043 · Cited by 14
Metcalf, R., Akinbobola, A., Woodford, L., & Quilliam, R. S. (2025) · Environmental Science and Pollution Research · doi:10.1007/s11356-025-36558-2 · Cited by 13
Name changes for fungi of medical importance, 2022–2024
Borman, A. M., Abdolrasouli, A., & Johnson, E. M. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.02041-24 · Cited by 13
Wani, M. Y., Ahmad, A., Aqlan, F. M., & Al‐Bogami, A. S. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128922 · Cited by 13
Identification of Candida auris by PCR and assessment of biofilm formation by crystal violet assay
Singh, P., Srivastava, S., Malhotra, R., & Mathur, P. (2023) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2023.100421 · Cited by 16
Genomic epidemiology of human candidaemia isolates in a tertiary hospital
Chew, K. L., Achik, R., Osman, N. H., Octavia, S., & Teo, J. W. P. (2023) · Microbial Genomics · doi:10.1099/mgen.0.001047 · Cited by 17
“In addition, Candida auris has joined the fray causing a global outbreak in ICUs, with the capacity to acquire resistance against azoles, echinocandins, as well as polyenes [6–8].”
Tools and techniques to identify, study, and control Candida auris
Carty, J., Chowdhary, A., Bernstein, D. A., & Thangamani, S. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011698 · Cited by 16
Self-citationSomething wicked this way comes: What health care providers need to know about Candida auris
Schwartz, I. S., Sw, S., & Dingle, T. (2018) · Canada Communicable Disease Report · doi:10.14745/ccdr.v44i11a01 · Cited by 14
“Resistance to two antifungal classes occurred in 41% of global isolates tested (5).”
BackgroundInfluentialMitochondrial Genome Sequences of the Emerging Fungal Pathogen Candida auris
Misas, E., Chow, N. A., Gómez, O. M., Muñoz, J. F., McEwen, J. G., Litvintseva, A. P., & Clay, O. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.560332 · Cited by 14
“…regions, namely South Asia (clade I), East Asia (clade II), South Africa (clade III) and South America (clade IV), with relatively low genetic variation within the clades (Lockhart et al., 2017b); recently a fifth clade was identified, which included a single isolate from Iran (Chow et al., 2019).”
BackgroundMethodResultInfluentialSelf-citationSchwartz, I. S., & Dingle, T. C. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.190433 · Cited by 14
Getahun, H. (2023) · Sustainable development goals series · doi:10.1007/978-3-031-33851-9_22 · Cited by 16
Galgóczy, L., & Marx, F. (2019) · Microorganisms · doi:10.3390/microorganisms7010016 · Cited by 14
Şengel, B. E., Ekren, B. Y., Sayın, E., Çerikçioğlu, N., Sezerman, O. U., & Odabaşı, Z. (2023) · Mycopathologia · doi:10.1007/s11046-023-00787-1 · Cited by 15
Discovery of Lead 2-Thiazolylhydrazones with Broad-Spectrum and Potent Antifungal Activity
Oliveira, N. J. C., dos Santos, V. S., Pierotte, I. C., Leocádio, V. A. T., Santana, L. F. D. A., Marques, G., Protti, Í. F., Braga, S. F. P., Kohlhoff, M., Freitas, T. R., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01105 · Cited by 12
Unveiling the bioactive potential of Actinomycetota from the Tagus River estuary
dos Santos, J. D. N., Pinto, E., Martín, J., Vicente, F., Reyes, F., & Lage, O. M. (2024) · International Microbiology · doi:10.1007/s10123-024-00483-0 · Cited by 12
“Regarding fungi, reports on Candida spp. and Aspergillus spp. are increasingly worrisome, with 90% of Candida auris isolates being resistant to fluconazole and 33% to amphotericin B (Lockhart et al. 2017).”
The sphingolipid inhibitor myriocin increases Candida auris susceptibility to amphotericin B
Stieber, H., Junghanns, L., Wilhelm, H., Batliner, M., Aldejohann, A. M., Kurzai, O., & Martin, R. (2024) · Mycoses · doi:10.1111/myc.13723 · Cited by 13
Asadzadeh, M., Ahmad, S., Alfouzan, W. A., Al‐Obaid, I., Spruijtenburg, B., Meijer, E. F. J., Meis, J. F. G. M., & Mokaddas, E. M. (2024) · Antibiotics · doi:10.3390/antibiotics13090840 · Cited by 13
“Whole genome sequencing-based studies have identified six genetically distinct clades, and the vast majority of clinical C. auris isolates from South Asia and the Middle East exhibit resistance to fluconazole and belong to clade I [16–21].”
BackgroundMethodSelf-citationInvasive Fungal Infections in Immunocompromised Conditions: Emphasis on COVID-19
Kaur, M., Thakur, P., Verma, N., Choksket, S., Harshvardhan, Korpole, S., Devadatha, B., & Grover, V. (2024) · Current Microbiology · doi:10.1007/s00284-024-03916-1 · Cited by 13
Trichosporon asahii : emerging challenges in pathogenesis and drug resistance
Zhang, H., & Zhang, J. (2025) · Future Microbiology · doi:10.1080/17460913.2025.2457858 · Cited by 13
Rosario-Colon, J., EBERLE, K. E., & Xin, H. (2025) · iScience · doi:10.1016/j.isci.2025.112459 · Cited by 13
“4,23 We therefore sought to determine if opsonization of C. auris with C3.”
InfluentialInsights into Candida auris dispersal cells and their impact on antifungal resistance
Fayed, B. E. (2025) · BMC Microbiology · doi:10.1186/s12866-025-04055-8 · Cited by 13
León, M. G. F.-D., Betancourt-Cisneros, P., Martínez-Herrera, E. O., Zárate-Segura, P. B., Castro-Fuentes, C. A., & García-Salazar, E. (2025) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed10060155 · Cited by 14
“Unlike the other species, C. auris is a non-commensal yeast, which is usually resistant to at least two of the main classes of systemic antifungals (93% are resistant to fluconazole, 35% to amphotericin B, and 7% to echinocandins) [5], limiting treatment options for patients [6].”
Candida auris Testing by the Antimicrobial Resistance Laboratory Network, United States, 2022–2023
Laury, J., Forsberg, K., Berkow, E. L., Jones, S., Sexton, D. J., Sievert, D. M., Lockhart, S. R., Gold, J. A. W., & Lyman, M. (2026) · Emerging infectious diseases · doi:10.3201/eid3202.251043 · Cited by 15
Self-citationThe dual role of azoles: lifesaving antifungals and drivers of resistance – a One Health perspective
Roohi, B., Tyndall, J. D. A., Svoboda, T., de Hoog, S., Crous, P. W., Monk, B. C., Strobl, B., Weißenbacher, A., Strauss, J., Verweij, P. E., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71762-9 · Cited by 15
“Withinthisresistancepro fi le,treatmentoptionsarelimited and current guidelines recommend echinocandins as the preferred initial therapy for Ca. auris infections 164,165 .”
Lam, L. M. T., Dufresne, P. J., Longtin, J., Sedman, J., & Ismail, A. A. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.01739-18 · Cited by 15
Cell Surface Expression of Nrg1 Protein in Candida auris
Paudyal, A., & Vediyappan, G. (2021) · Journal of Fungi · doi:10.3390/jof7040262 · Cited by 14
“Candida auris is an emerging multi-drug resistant human fungal pathogen detected in many countries simultaneously [2].”
BackgroundSteinmann, J., Schrauzer, T., Kirchhoff, L., Meis, J. F. G. M., & Rath, P. (2021) · Journal of Fungi · doi:10.3390/jof7050380 · Cited by 13
Self-citationNew Peptide Based Fluconazole Conjugates with Expanded Molecular Targets
Brankiewicz, W., Okońska, J., Serbakowska, K., Lica, J. J., Dráb, M., Ptaszyńska, N., Łęgowska, A., Rolka, K., & Szweda, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040693 · Cited by 13
Ahn, H., Lee, R., Cho, S., & Lee, D. (2022) · Blood Research · doi:10.5045/br.2022.2022036 · Cited by 14
“Moreover, most strains are resistant to at least one antifungal agent [29].”
BackgroundTran, H. N. H., Udoh, S., Russell, G., Okeyoyin, O. R., Aftab, S., Rodriguez, I., Tabe, E. S., & Adukwu, E. C. (2022) · Applied Microbiology · doi:10.3390/applmicrobiol2020030 · Cited by 15
“As a result of the globally emerging threats of multidrug resistant C. auris [54], further research by Hamdy et al. [55] led to the development of novel antifungal drugs that are effective against not only C. albicans, but also C. auris through the use of cuminaldehyde isolated from the Calligonum…”
Background
Metadata
- Authors
- Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., Berkow, E. L., Castanheira, M., Magobo, R. E., Jabeen, K., Asghar, R. J., Meis, J. F., Jackson, B., Chiller, T., & Litvintseva, A. P.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Aga Khan University (PK)
- University of Delhi (IN)
- National Health Laboratory Service (ZA)
- Universidade Federal de São Paulo (BR)
- Universidad del Zulia (VE)
- Broad Institute (US)
- JMI Laboratories (US)
- Radboud University Nijmegen (NL)
- ORCID
- Lockhart, Shawn R.
- Vallabhaneni, Snigdha
- Farooqi, Joveria
- Chowdhary, Anuradha
- Govender, Nelesh P.
- Colombo, Arnaldo Lopes
- Cuomo, Christina A.
- Desjardins, Christopher A.
- Berkow, Elizabeth L.
- Castanheira, Mariana
- Magobo, Rindidzani E.
- Jabeen, Kauser
- Asghar, Rana J.
- Meis, Jacques F.
- Jackson, Brendan
- Chiller, Tom
- Litvintseva, Anastasia P.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10-20
- Volume
- 64
- Issue
- 2
- Pages
- 134-140
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC5215215
- OpenAlex
- W2536287248
- Semantic Scholar
- c8d8e54651d8fb7a7ece68270cd2630d1cd0df39
- Cited by
- 1,662
- References
- 32
- Citations by year
- 2026: 196 · 2025: 194 · 2024: 203 · 2023: 186 · 2022: 160 · 2021: 178 · 2020: 187 · 2019: 152 · 2018: 116 · 2017: 81 · 2016: 5
- FWCI
- 108.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- public-domain
- Locations
- Clinical Infectious Diseases (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (U19AI110818)
- United States Agency for International Development (4-338/PAK-US/HEC/2010/932)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- Candida auris, multidrug resistance, antifungal resistance, clonal populations, ERG11 mutations, azole resistance, fluconazole resistance, bloodstream infection, invasive candidiasis, nosocomial infections, risk factors, transmission, whole genome sequencing, antifungal susceptibility
- MeSH terms
- Whole Genome Sequencing, Adolescent, Adult, Aged, Antifungal Agents, Candida, Candidiasis, Child, Child, Preschool, Cytochrome P-450 Enzyme System, Female, Humans, Infant, Infant, Newborn, Male, Microbial Sensitivity Tests, Middle Aged, Mutation, Phylogeny, RNA, Ribosomal, 28S, Global Health, Genome, Fungal, Drug Resistance, Multiple, Polymorphism, Single Nucleotide, DNA, Ribosomal Spacer, Drug Resistance, Fungal, Young Adult, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.